June 13 (Reuters) - Moderna said on Thursday its next-generation COVID-19 vaccine candidate met its main goal in a late-stage study by showing vaccine efficacy that was non-inferior compared with the company's commercial shot. (Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel)